title: A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.
abstract: OBJECTIVE
  The superiority of risperidone long-acting injection (RLAI) over oral typical and atypical antipsychotics demonstrated in previous studies may be related to the improved drug compliance. The aim of the 12-week randomized, single-blind study was to test whether the superiority of RLAI remained among hospitalized patients that drug compliance could be optimally controlled.
  
  
  METHODS
  Fifty hospitalized stable schizophrenic patients, who had maintained on oral risperidone for more than 3 months, were randomized to the RLAI and oral risperidone group. Finally 49 patients (98 %) completed the study, and no dose change of oral risperidone, or RLAI was noted among all patients.
  
  
  RESULTS
  The RLAI group showed significantly increased positive score of Positive and Negative Syndrome Scale (PANSS) than the risperidone group (0.72 +/- 3.52 vs. -1.24 +/- 3.81, p = 0.022), but without significance difference for the PANSS total, negative and general psychopathology scores. The RLAI group also showed a significantly improved Udvalg for Kliniske Undersogelser (UKU) Scale (p = 0.037), social life domains of Short-Form Health Survey (SF-36) (p = 0.011), and reduced prolactin level (p = 0.001).
  
  
  CONCLUSIONS
  The results indicated that with optimal controlling of drug compliance among hospitalized patients, RLAI showed no benefit of efficacy over oral risperidone, but with advantages of improved side-effect profiles, social life ratings, and reduced prolactin levels.
authors.affiliation: Institute of Public Health, National Yang-Ming University, 155 Li-Nong Street section 2, Shihpai, Taipei 112, Taiwan.
authors.forename: Y M
authors.initials: YM
authors.lastname: Bai
authors.forename: T T
authors.initials: TT
authors.lastname: Chen
authors.forename: B
authors.initials: B
authors.lastname: Wu
authors.forename: C H
authors.initials: CH
authors.lastname: Hung
authors.forename: W K
authors.initials: WK
authors.lastname: Lin
authors.forename: T M
authors.initials: TM
authors.lastname: Hu
authors.forename: C-Y
authors.initials: CY
authors.lastname: Lin
authors.forename: P
authors.initials: P
authors.lastname: Chou
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016037:Single-Blind Method
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone